Teva Pharmaceutical Industries Ltd. — Director's Dealing 2021

Jun 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2021-06-05

Reporting Person: MIGNONE ROBERTO (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-05	Ordinary Shares	M	6041	—	Acquired	31618	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-05	Restricted Share Units	$	M	6041	Disposed		Ordinary Shares (6041)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	1500000	Indirect

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3: The 1,500,000 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Partners, L.P. and Swiftcurrent Offshore
Master, Ltd. (the "Funds"). Bridger Management, LLC is the investment adviser to the Funds and Mr. Mignone is the manager of Bridger
Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may
be deemed to beneficially own the Ordinary Shares held of record by the Funds. Mr. Mignone disclaims beneficial ownership of the Ordinary
Shares held of record by the Funds except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an
admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Funds for purposes of Section 16, or for any
other purpose.

F4: Restricted share units were granted on June 5, 2018 and vested on June 5, 2021.